Dermira, Inc. (DERM): Price and Financial Metrics

Dermira, Inc. (DERM): $3.48

0.10 (-2.79%)

POWR Rating

Component Grades








Add DERM to Watchlist
Sign Up

Industry: Biotech




in industry

DERM Price/Volume Stats

Current price $3.48 52-week high $8.11
Prev. close $3.58 52-week low $1.02
Day low $3.40 Volume 102,400
Day high $3.64 Avg. volume 194,242
50-day MA $3.86 Dividend yield N/A
200-day MA $3.70 Market Cap 69.36M

DERM Stock Price Chart Interactive Chart >

Dermira, Inc. (DERM) Company Bio

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. The company was founded in 2010 and is based in Menlo Park, California.

DERM Latest News Stream

Event/Time News Detail
Loading, please wait...

DERM Latest Social Stream

Loading social stream, please wait...

View Full DERM Social Stream

Latest DERM News From Around the Web

Below are the latest news stories about JOURNEY MEDICAL CORP that investors may wish to consider to help them evaluate DERM as an investment opportunity.

Here's What Could Help Journey Medical Corporation (DERM) Maintain Its Recent Price Strength

Journey Medical Corporation (DERM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Yahoo | December 27, 2023

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 27, 2023

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

Yahoo | December 26, 2023

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.

Yahoo | December 21, 2023

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Yahoo | December 20, 2023

Read More 'DERM' Stories Here

DERM Price Returns

1-mo -8.90%
3-mo -31.36%
6-mo 7.08%
1-year 116.15%
3-year N/A
5-year N/A
YTD -39.58%
2023 200.00%
2022 -64.31%
2021 N/A
2020 N/A
2019 N/A

Continue Researching DERM

Want to do more research on NA's stock and its price? Try the links below:

NA (DERM) Stock Price | Nasdaq
NA (DERM) Stock Quote, History and News - Yahoo Finance
NA (DERM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!